SUMMARY Cerebral blood flow was measured in eight patients who were being treated with dopamine in order to maintain cerebral perfusion after the onset of delayed postoperative ischaemia following intracranial aneurysm surgery. Measurements were made whilst on treatment and repeated either during a reduction in the dosage or withdrawal of dopamine. There was a significant fall in cerebral blood flow in both hemispheres in all eight patients. Clinical deterioration was observed in seven of nine instances in which cerebral blood flow fell by 25% or more of the value while on dopamine treatment. There were no episodes of deterioration in six tests where the fall in cerebral blood flow was less than 25% of the starting value. It is suggested that cerebral blood flow measurement can be useful in predicting when it is safe to withdraw dopamine treatment in these patients. Hypertensive treatment should be maintained if a withdrawal test is associated with a fall in cerebral blood flow of 25% or more.
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With the resurgence of interest in earlier surgery for patients with ruptured intracranial aneurysms, there is an increased incidence of cerebral ischaemia several hours or days after operation. In an attempt to prevent or treat the intracranial arterial spasm thought to underly such deterioration, many different substances have been tried.' It is increasingly realised that clinical deterioration may be the result of a relative fall in cerebral perfusion pressure (CPP) and successful reversal of ischaemic deficits has been reported with elevation of CPP either with hypervolaemic treatment2 or with pharmacologically induced hypertension.3 Hypertensive treatment may need to be continued for many days, and premature withdrawal may precipitate a further episode of clinical deterioration, either immediately or after a delay. The aim of the present study was to determine if measurements of cerebral blood flow could be used to predict deterioration following withdrawal of hypertensive treatment, and to evaluate its usefulness as a guide to the timing of its cessation.
Patients and methods
We report eight patients who had suffered a subarachnoid operative ischaemia was diagnosed clinically when focal neurological signs developed or when there was deterioration in the level of consciousness; in these patients its clinical onset was diagnosed from one to six days after operation. Hypertensive treatment was instituted with dopamine (800 mg in 500 ml of saline) infused via a central line at a rate of 5 ml per hour, increasing the infusion by 5 ml per hour every 5 minutes until the systolic blood pressure reached 180 mm Hg. The lowest dose of dopamine required to maintain a systolic blood pressure close to 180 mm Hg was used. The dosage tended to rise with the passage of time as a manifestation of tachyphylaxis, but the maximum dose used was 70 ml per hour (30 ,ug/kg/min).
To counteract this effect, desmopressin (4 ,ug) was given intramuscularly daily during treatment and a minimum daily intake of 3 litres of fluid was ensured. Haemoglobin and serum electrolyte levels were estimated daily, and blood was transfused if the haemoglobin fell below 11 g/dl.
Measurement of cerebral blood flow The two minute slope inhalation method for the measurement of cerebral blood flow was used, according to the technique of Wyper et al.4 The method provided a noninvasive assessment of hemisphere cerebral blood flow, which was repeated after reducing the dose of dopamine to the lowest level that could be tolerated safely by the patients. Paired parieto-temporal collimated external detectors were used, providing a simultaneous measurement of cerebral blood flow in each hemisphere. Corrections were applied to minimise detector "cross talk". The theory of cerebral blood flow measurement using inert diffusable tracers (133 xenon) with this apparatus has been described in detail.5 A spirometer with open and closed circuit systems was employed, into which a mixture of 133 xenon and air was introduced, to give a specific activity of approximately 1.0 mCi/litre. A C02 absorber system was incorporated in the closed circuit. End-tidal C02 and 133 xenon concentrations were measured continuously, using a capnograph and a scintillation counter. After an initial acclimatisation period while breathing on the open circuit, and once the end-tidal C02 had become steady, a background count was measured, and the patient was switched to the closed circuit. The 133 xenon and air mixture was breathed for two minutes and then the spirometer was switched back to open circuit. After a 30 second lag phase, so that the patient began breathing fresh air again, the clearance of 133 xenon from the head was measured using the two detectors. Calculation of clearance rates, and thus cerebral blood flow, was performed using a three dimensional nomogram developed for this purpose.6 The capnograph was calibrated against reference gases. Similar cerebral blood flow estimations were made in normal volunteers and an age-matched flow value was calculated from the linear regression formula that we have previously reported.' The rate of dopamine infusion was reduced using an infusion pump with a rate controller, while mean blood pressure was measured and clinical examination was recorded. If ml/100 g/min. The initial mean cerebral blood flow on the first day that the dopamine withdrawal test was performed was 34-1 ± 1-7 ml/ 100 g/min, in the damaged hemisphere and 38-3 ± 3.7 ml/100 g/min in the undamaged hemisphere (table 1) . After withdrawal, or on the lowest safe dosage of dopamine, mean cerebral blood flow in the damaged hemisphere was 27-1. ± 1*7 ml/100 g/min and in the undamaged hemisphere was 31-5 ± 3.9 ml/100 g/ min. The differences between the mean cerebral blood Row values at the highest and lowest dosages of dopamine were significant (p < 0.05) in both the damaged and the undamaged hemispheres (table  1) . Where patients deteriorated, dopamine therapy was resumed, and the withdrawal test was repeated at a later stage. This occurred in four patients, result- The maximum percentage fall in cerebral blood flow (% dCBF) in either hemisphere on each occasion when CBF was measured, the number of days after starting the dopamine infusion (day/dopamine) and the occurrence of deterioration. (+).
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